Results 91 to 100 of about 3,887,212 (164)

Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review

Pharmaceuticals
This review article explores the evolving landscape of Molecular Radiotherapy (MRT), emphasizing Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumours (NETs).
Paul M. D. Gape, Michael K. Schultz, Graeme J. Stasiuk, Samantha Y. A. Terry   +3 more
doaj   +1 more source

Peptide receptor radionuclide therapy in the management of neuroendocrine tumors (Neoplasms)*: Fundamentals and salient clinical practice points for medical oncologists

Indian Journal of Medical and Paediatric Oncology, 2019
This editorial commentary is an expert summary of “Peptide Receptor Radionuclide Therapy (PRRT),” encompassing the essential fundamentals and salient clinical practice points, deliberated and designed in a point-wise manner with theme-based subheadings ...
Sandip Basu, Rahul Parghane, Rohit Ranade, Pradeep Thapa, Anant Ramaswamy, Vikas Ostwal, Bhawna Sirohi, Dipanjan Panda, Shailesh V Shrikhande   +8 more
doaj   +1 more source

Glucagon-like peptide-1 receptor imaging for localization of insulinomas [PDF]

, 2009
The surgical removal of insulinomas is hampered by difficulties to localize it using conventional radiological procedures. Recently these tumors were shown to exhibit a very high density of glucagon-like peptide-1 receptors (GLP-1R) in vitro that may be ...
Clerici, Thomas, Forrer, Flavio, Gloor, Beat, Reubi, Jean Claude, Rahel Sahli, Mäcke, Helmut R., Brändle, Michael, Beat Gloor, Martius, Ferdinand, Damian Wild, Reubi, Jean-Claude, Thomas Clerici, Flavio Forrer, Maecke, Helmut, Wild, Damian, Emanuel Christ, Ferdinand Martius, Christ, Emanuel, Sahli, Rahel, Jean Claude Reubi, Michael Brändle, Helmut Maecke   +21 more
core   +3 more sources

Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.

, 2012
Neuroendocrine tumors (NETs) are rare tumors with variable malignant behavior. The majority of NETs express increased levels of somatostatin (SST) receptors, particularly SST2 receptors.
Forrer F, Nicolas G, Giovacchini G
core   +1 more source

Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.

, 2017
OBJECTIVES The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT).
Bushnell DL, Sharma N, Engelman EG, Müller-Brand J, Howe JR, Zimmerman MB, Halfdanarson TR, OʼDorisio MS, OʼDorisio TM, Menda Y, Naraev BG   +10 more
core   +1 more source

Application of the Linear-Quadratic model to targeted radionuclide therapy [PDF]

, 2011
PhDThe principal aim of this work was to test the hypothesis that the Linear-Quadratic (LQ) model of cell survival, developed for external beam radiotherapy (EBRT), could be extended to targeted radionuclide therapy (TRT) in order to predict dose ...
Murray, Iain
core   +2 more sources

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors

Frontiers in Oncology, 2019
Purpose: To develop a care process model for the delivery of peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-Dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs ...
Pashtoon Murtaza Kasi, Catherine L. Maige, Faisal Shahjehan, Jessica M. Rodgers, Debora L. Aloszka, Ashton Ritter, Margaret L. Andrus, Jessica M. Mcmillan, Kabir Mody, Akash Sharma, Manoj K. Jain   +10 more
doaj   +1 more source

Peptide-receptor radionuclide therapy for endocrine tumors

, 2009
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is a promising option for the treatment of somatostatin-receptor-positive endocrine tumors.
Martijn van Essen, Essen, Martijn, Roelf Valkema, Eric P. Krenning, Dik J. Kwekkeboom, Krenning, Eric, Valkema, R., Jong, Marion, Kwekkeboom, Dik, Boen L. R. Kam, Kam, BLR, Marion de Jong   +11 more
core   +1 more source

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression. [PDF]

EJNMMI Res, 2023
Jahn U, Garske-Román U, Sandström M, Lubberink M, Sundin A.   +4 more
europepmc   +1 more source

Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy

Case Reports in Dermatological Medicine
Neuroendocrine neoplasms (NENs) encompass a diverse range of biologically and behaviorally distinct epithelial malignancies that derive from neuroendocrine cells. These neoplasms are able to secrete a variety of bioactive amines or peptide hormones.
Eleanor Tung-Hahn, Ghassan El-Haddad, Jonathan Strosberg   +2 more
doaj   +1 more source